A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

Roche brings subcutaneous Atezolizumab to India, shot costs Rs 3.7 lakh per dose with most patients needing around six doses ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

India’s new 7-minute lung cancer immunotherapy injection may improve treatment convenience, survival outcomes, and patient ...

Tens of thousands of patients could benefit from a ‘rapid’ new immunotherapy jab on the NHS for over a dozen different cancers, which can be given in just 60 seconds.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a subcutaneous injectable version of the cancer drug nivolumab (Opdivo, Bristol Myers Squibb). NHS England said it would be ...

For individuals living with cancer, navigating treatment can be a significant challenge, often requiring substantial time commitments and disruptions to daily life. Traditionally, immunotherapy ...

Approved by the Drugs Controller General of India around two months ago for adjuvant and metastatic non-small cell lung ...

– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq – – New subcutaneous (SC ...

Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".